Related references
Note: Only part of the references are listed.Impact of inflammation on vascular disease in hypertension
Agostino Virdis et al.
MATURITAS (2014)
Inflammatory Arthritis in Patients With Myelodysplastic Syndromes A Multicenter Retrospective Study and Literature Review of 68 Cases
Arsene Mekinian et al.
MEDICINE (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Overexpression of miR-125a in Myelodysplastic Syndrome CD34+ Cells Modulates NF-κB Activation and Enhances Erythroid Differentiation Arrest
Irene Ganan-Gomez et al.
PLOS ONE (2014)
Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-κB Gene Network
Jing Fang et al.
CELL REPORTS (2014)
Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
Garrett W. Rhyasen et al.
CANCER CELL (2013)
Differential IRAK signaling in hematologic malignancies
Garrett W. Rhyasen et al.
EXPERIMENTAL HEMATOLOGY (2013)
Tumor Necrosis Factor-α Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation
Moshe Sade-Feldman et al.
IMMUNITY (2013)
Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome
L. Sokol et al.
LEUKEMIA (2013)
Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells
S. Geyh et al.
LEUKEMIA (2013)
Toll-like receptor alterations in myelodysplastic syndrome
Y. Wei et al.
LEUKEMIA (2013)
Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and overexpression of JMJD3 in human myelodysplastic syndrome CD34+cells
Y. Wei et al.
LEUKEMIA (2013)
Overexpression of the Toll-Like Receptor (TLR) Signaling Adaptor MYD88, but Lack of Genetic Mutation, in Myelodysplastic Syndromes
Sophie Dimicoli et al.
PLOS ONE (2013)
Effector memory regulatory T-cell expansion marks a pivotal point of immune escape in myelodysplastic syndromes
Adam W. Mailloux et al.
ONCOIMMUNOLOGY (2013)
Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1
Jing Fang et al.
BLOOD (2012)
Functional characteristics of mesenchymal stem cells derived from bone marrow of patients with myelodysplastic syndromes
Zhi-Gang Zhao et al.
CANCER LETTERS (2012)
Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome
Adam W. Mailloux et al.
JOURNAL OF IMMUNOLOGY (2012)
The Different Immunoregulatory Functions of Mesenchymal Stem Cells in Patients with Low-Risk or High-Risk Myelodysplastic Syndromes
Zhigang Zhao et al.
PLOS ONE (2012)
Intrinsic Growth Deficiencies of Mesenchymal Stromal Cells in Myelodysplastic Syndromes
Carmen Mariana Aanei et al.
STEM CELLS AND DEVELOPMENT (2012)
Myelodysplastic Syndrome Presenting as Generalized Granulomatous Dermatitis
Samuel J. Balin et al.
ARCHIVES OF DERMATOLOGY (2011)
Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes
Irene Bouchliou et al.
CLINICAL IMMUNOLOGY (2011)
Niche contributions to oncogenesis: emerging concepts and implications for the hematopoietic system
Marc H. G. P. Raaijmakers
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Targeting Immune Dysregulation in Myelodysplastic Syndromes
Matthew J. Olnes et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice
Mark P. Boldin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
NF-κB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies
Jimmy L. Zhao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes
Xiang Li et al.
BLOOD (2010)
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study
Bart L. Scott et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Innate Immune Signaling in the Myelodysplastic Syndromes
Daniel T. Starczynowski et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2010)
The role of p38 mitogen-activated protein kinase in serum-induced leukemia inhibitory factor secretion by bone marrow stromal cells from pediatric myelodysplastic syndromes
Simone V. da Costa et al.
LEUKEMIA RESEARCH (2010)
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Marc H. G. P. Raaijmakers et al.
NATURE (2010)
Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype
Daniel T. Starczynowski et al.
NATURE MEDICINE (2010)
IL-17-producing CD4+ T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
Shahram Y. Kordasti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses
Y. -H. Wang et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2009)
The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer
Jan M. Ehrchen et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Altered naive and memory CD4+T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome
J. X. Zou et al.
LEUKEMIA (2009)
Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q-syndrome
O. Lopez-Villar et al.
LEUKEMIA (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
High-resolution whole genome tiling path array CGH analysis of CD34+ cells from patients with low-risk myelodysplastic syndromes reveals cryptic copy number alterations and predicts overall and leukemia-free survival
Daniel T. Starczynowski et al.
BLOOD (2008)
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
Elaine M. Sloand et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Inhibition of p38 alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment
Tony Navas et al.
LEUKEMIA & LYMPHOMA (2008)
Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells
Eugenia Flores-Figueroa et al.
LEUKEMIA RESEARCH (2008)
Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function
A. Mario Marcondes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The role of the immune system in myelodysplasia: Implications for therapy
Elaine M. Sloand et al.
SEMINARS IN HEMATOLOGY (2008)
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
Lukasz P. Gondek et al.
BLOOD (2008)
Location, location, location: The cancer stem cell niche
Julie B. Sneddon et al.
CELL STEM CELL (2007)
Mrp8 and Mrp14 are endogenous activators of Toll- like receptor 4, promoting lethal, endotoxin-induced shock
Thomas Vogl et al.
NATURE MEDICINE (2007)
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Shahram Y. Kordasti et al.
BLOOD (2007)
Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin
Z. Y. Lim et al.
LEUKEMIA (2007)
Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment
Carl R. Walkley et al.
CELL (2007)
A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency
Carl R. Walkley et al.
CELL (2007)
NF-κB inhibition sensitizes to starvation-induced cell death in high-risk myelodysplastic syndrome and acute myeloid leukemia
C. Fabre et al.
ONCOGENE (2007)
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors
Pearlie K. Epling-Burnette et al.
BLOOD (2007)
Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes
Christos I. Maratheftis et al.
CLINICAL CANCER RESEARCH (2007)
Inappropriate notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes
Gergely Varga et al.
PATHOLOGY & ONCOLOGY RESEARCH (2007)
Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors
Tony A. Navas et al.
BLOOD (2006)
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
Alan List et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Normal stem cells and cancer stem cells: The niche matters
Linheng Li et al.
CANCER RESEARCH (2006)
Role of immature myeloid cells in mechanisms of immune evasion in cancer
S Kusmartsev et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
NF-κB and FLEP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)
DMB Kerbauy et al.
BLOOD (2005)
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
EM Sloand et al.
BLOOD (2005)
Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow
Y Ueda et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Stroma-mediated dysregulation of myelopolesis in mice lackingk lκBα
RA Rupec et al.
IMMUNITY (2005)
Mesenchymal stem cells in myelodysplastic syndromes:: phenotypic and cytogenetic characterization
E Flores-Figueroa et al.
LEUKEMIA RESEARCH (2005)
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
M Stadler et al.
LEUKEMIA (2004)
Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities
GB Chen et al.
BLOOD (2004)
Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells
HJ Deeg et al.
LEUKEMIA RESEARCH (2004)
Expression of FLIPLong and FLIPShort in bone marrow mononuclear and CD34+ cells in patients with myelodysplastic syndrome:: correlation with apoptosis
M Benesch et al.
LEUKEMIA (2003)
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
DP Steensma et al.
BLOOD (2003)
Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow
WK Hofmann et al.
BLOOD (2002)
Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
JN Kochenderfer et al.
BLOOD (2002)
Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia
C Selleri et al.
CANCER (2002)
Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study
HJ Deeg et al.
LEUKEMIA (2002)
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
A Raza et al.
BLOOD (2001)
Ryanodine receptor point mutant E4032A reveals an allosteric interaction with ryanodine
JD Fessenden et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
